Your institution may have access to this item. Find your institution then sign in to continue.
Title
Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
Authors
Boonen, A; van der Heijde, D; Severens, J L; Boendermaker, A; Landewé, R; Braun, J; Brandt, J; Sieper, J; van der Linden, Sj
Abstract
To estimate the incremental cost-utility of etanercept and infliximab compared with usual care in active ankylosing spondylitis.
Publication
Annals of the rheumatic diseases, 2006, Vol 65, Issue 2, p201